Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 45 entries
View as:

A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis

Phase: N/A Priority: Normal
NCT ID: NCT02473952 Org: User:
Start: 08/31/15 End: 01/31/18 Due: 01/31/19

Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT02872142 Org: User:
Start: 08/29/16 End: 08/15/19 Due: 08/15/20

Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin Deficiency

Phase: N/A Priority: Normal
NCT ID: NCT02870309 Org: User:
Start: 07/29/16 End: 03/15/17 Due: 03/15/18

A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency

Phase: N/A Priority: Normal
NCT ID: NCT04566692 Org: User:
Start: 11/24/20 End: 07/25/22 Due: 07/25/23

Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients

Phase: N/A Priority: Normal
NCT ID: NCT00220766 Org: User:
Start: 08/31/02 End: 03/31/04 Due: 03/31/05

Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency

Phase: N/A Priority: Normal
NCT ID: NCT02604810 Org: User:
Start: 01/31/16 End: 12/31/17 Due: 12/31/18

Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT01684410 Org: User:
Start: 08/31/12 End: 10/31/13 Due: 10/31/14

A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations

Phase: N/A Priority: Normal
NCT ID: NCT02413580 Org: User:
Start: 03/31/15 End: 04/30/18 Due: 04/30/19

A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion

Phase: N/A Priority: Normal
NCT ID: NCT00418483 Org: User:
Start: 03/31/07 End: 04/30/10 Due: 04/30/11

A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients

Phase: N/A Priority: Normal
NCT ID: NCT04847141 Org: User:
Start: 04/28/21 End: 12/27/21 Due: 12/27/22

Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites

Phase: N/A Priority: Normal
NCT ID: NCT03451292 Org: User:
Start: 07/24/18 End: 05/21/24 Due: 05/21/25

Study Evaluating IGSC 20% Flexible Dosing in Treatment-Experienced and Treatment-Naive Subjects With Primary Immunodeficiency

Phase: N/A Priority: Normal
NCT ID: NCT03814798 Org: User:
Start: 12/31/19 End: 09/30/20 Due: 09/30/21

Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%

Phase: N/A Priority: Normal
NCT ID: NCT03702920 Org: User:
Start: 02/21/19 End: 04/14/25 Due: 04/14/26

Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease

Phase: N/A Priority: Normal
NCT ID: NCT02472665 Org: User:
Start: 12/31/13 End: 12/31/26 Due: 12/31/27

Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)

Phase: N/A Priority: Normal
NCT ID: NCT02870348 Org: User:
Start: 07/29/16 End: 02/16/21 Due: 02/16/22

A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency

Phase: N/A Priority: Normal
NCT ID: NCT00389324 Org: User:
Start: 11/30/06 End: 08/31/08 Due: 08/31/09

Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency

Phase: N/A Priority: Normal
NCT ID: NCT02806986 Org: User:
Start: 06/30/16 End: 05/15/19 Due: 05/15/20

Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency

Phase: N/A Priority: Normal
NCT ID: NCT01465958 Org: User:
Start: 11/30/11 End: 10/31/13 Due: 10/31/14

Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital Afibrinogenemia

Phase: N/A Priority: Normal
NCT ID: NCT02281500 Org: User:
Start: 07/22/16 End: 11/11/19 Due: 11/11/20

Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis

Phase: N/A Priority: Normal
NCT ID: NCT02473965 Org: User:
Start: 06/30/15 End: 02/28/19 Due: 02/28/20

An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human)

Phase: N/A Priority: Normal
NCT ID: NCT02139657 Org: User:
Start: 03/31/14 End: 05/31/14 Due: 05/31/15

Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency

Phase: N/A Priority: Normal
NCT ID: NCT01213043 Org: User:
Start: 11/30/10 End: 01/31/12 Due: 01/31/13

A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients

Phase: N/A Priority: Normal
NCT ID: NCT01014975 Org: User:
Start: 11/30/09 End: 02/28/14 Due: 02/28/15

Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE)

Phase: N/A Priority: Normal
NCT ID: NCT00263887 Org: User:
Start: 12/31/03 End: 01/31/07 Due: 01/31/08

Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP

Phase: N/A Priority: Normal
NCT ID: NCT00220727 Org: User:
Start: 07/31/03 End: 10/31/03 Due: 10/31/04